USPTO Examiner OLSON ANDREA STEFFEL - Art Unit 1693

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19183918MODIFIED CELLULOSE AND THE PREPARATION METHOD AND APPLICATION THEREOFApril 2025September 2025Allow510NoNo
18438664MATERIALS AND METHODS FOR PURIFYING DNA, RNA, AND POLYPEPTIDESFebruary 2024March 2025Abandon1320YesNo
18386050METHODS OF TREATING HEMATOLOGIC CANCERSNovember 2023December 2025Abandon2510NoNo
18384183CROSS-LINKED MALTODEXTRINS FOR THE ORAL DELIVERY OF BIOLOGICAL ACTIVESOctober 2023October 2025Abandon2410NoNo
18477609TOPICAL COMPOSITIONS DESIGNATED TO MAINTAIN AND/OR RESTORE THE INTEGRITY OF THE MUCOSA AND DAMAGED EPIDERMISSeptember 2023February 2025Allow1610NoNo
18374500TREATMENT REGIMENSSeptember 2023September 2025Abandon2310NoNo
18283101CYCLODEXTRIN COMPLEXES OF SPECIALIZED PRORESOLVING MEDIATORSSeptember 2023October 2025Allow2521NoNo
18463658PROTECTED TETRASACCHARIDES, THEIR PROCESS OF PREPARATION AND THEIR USE AS TRANSGLUCOSYLASE ACCEPTOR SUBSTRATES IN THE CHEMO-ENZYMATIC SYNTHESIS OF SHIGELLA FLEXNERI SPECIFIC OLIGOSACCHARIDESSeptember 2023February 2026Allow3021NoNo
18243156Compounds and Methods for Modulating GFAPSeptember 2023August 2025Allow2310NoNo
18460637APPLICATION OF HYALURONIC ACID IN PREPARING MEDICINES FOR PREVENTING OR TREATING FERROPTOSIS-RELATED DISEASESSeptember 2023December 2024Allow1640NoNo
18459507COMPOSITION COMPRISING MANNOSE OLIGOSACCHARIDE AND PROCESS FOR MAKING SAME AND USE THEREOFSeptember 2023June 2025Abandon2110NoNo
18354837HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTSJuly 2023May 2025Abandon2210NoNo
18346935USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALSJuly 2023April 2025Allow2120NoNo
18336436ANTIBODY DRUG CONJUGATESJune 2023September 2024Allow1600NoNo
18039035COMPOSITION FOR USE IN TREATMENT OF A BIOFILM IN A SUBJECTMay 2023March 2026Allow3310NoNo
18322767SALTS AND POLYMORPHS OF CETHROMYCIN FOR THE TREATMENT OF DISEASEMay 2023April 2025Allow2310NoNo
18037561RED-LIGHT-MEDIATED NUCLEIC ACID ANCHORING-TYPE FLUORESCENT PROBE, AND PREPARATION METHOD THEREFOR AND USE THEREOFMay 2023October 2025Allow2900NoNo
18313671TREATMENT OF A BACTERIAL VAGINAL INFECTIONMay 2023May 2025Allow2410NoNo
18308842C-MANNOSIDE COMPOUNDS USEFUL FOR THE TREATMENT OF URINARY TRACT INFECTIONSApril 2023June 2025Allow2620NoNo
18137896COMPOUNDS, COMPOSITIONS, AND METHODS FOR ISOLATION OF NUCLEIC ACIDSApril 2023February 2026Allow3410NoNo
18301845NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOFApril 2023January 2025Allow2110NoNo
18135609Nicotinyl Riboside Compounds and Their UsesApril 2023March 2025Abandon2310NoNo
18299303MALTODEXTRIN AND PROCESS OF MAKING SAMEApril 2023March 2025Allow2310NoNo
18131727METHODS FOR REDUCING THE WEIGHT LOSS OR INCREASING THE WEIGHT OF A FELINE IN NEED THEREOFApril 2023January 2025Abandon2210NoNo
18131192DIAGNOSTIC DRUG, DIAGNOSTIC METHOD AND DIAGNOSTIC DEVICE FOR PERMEABILITY OF INTESTINAL MUCOSAApril 2023December 2024Allow2010NoNo
18130212SILICON CONTAINING DETECTABLE COMPOUNDSApril 2023February 2025Allow2220NoNo
18181467METHODS OF TREATMENT AND MAINTENANCE THERAPY FOR BLADDER CANCER USING GEMCITABINEMarch 2023March 2026Allow3640YesNo
18180900Nanofibrillated Cellulose FibersMarch 2023June 2025Allow2821NoNo
18117759COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERSMarch 2023August 2025Allow2920NoNo
18176609COMPOSITIONS AND METHODS FOR CAPPING RNASMarch 2023October 2024Allow2010NoNo
18043538ONE-STEP KIT-BASED SYNTHESIS OF 2-DEOXY-2-[18F]FLUORO-D-SORBITOLFebruary 2023July 2025Allow2810NoNo
18043377THERAPY TO STIMULATE HIPPOCAMPAL NEURAL PROGENITORS AND ADULT NEUROGENESISFebruary 2023January 2026Allow3410NoNo
18042703WATER-SOLUBLE 1,3-DIPHENYLGUANIDINE (DPG)-BASED SUPRAMOLECULAR INCLUSION COMPLEX AND PREPARATION METHOD AND USE THEREOFFebruary 2023December 2025Allow3410NoNo
18170167CONJUGATED OLIGONUCLEOTIDESFebruary 2023November 2024Abandon2110NoNo
18156511SELECTIVELY CONTROLLABLE CLEAVABLE LINKERSJanuary 2023August 2024Allow1910YesNo
18155730METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECTJanuary 2023February 2025Abandon2510NoNo
18002665ANTIVIRAL PHARMACEUTICAL COMPOSITIONDecember 2022January 2026Abandon3710NoNo
18011586ADJUVANT WITH TLR4 AGONIST ACTIVITYDecember 2022February 2026Abandon3810NoNo
18002232CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDSDecember 2022February 2026Allow3810NoNo
18009679DEVICE FOR SOLID/LIQUID EXTRACTION BY RADIAL ULTRASONIC IRRADIATION, AND ASSOCIATED EXTRACTION METHODDecember 2022January 2026Abandon3710NoNo
18062105METHOD FOR PRODUCING A POLYPHENOLIC COMPOSITION FROM BARLEY MALTDecember 2022October 2024Allow2210NoNo
17926341CHEMICAL FUNCTIONALIZATION OF CELLULOSIC MATERIALS WITH DIAZO COMPOUNDSNovember 2022November 2025Allow3610NoNo
17925986PHOTOSYNTHETICALLY CONTROLLED SPIRULINA EXTRACTS FOR TREATING THE CYTOKINE STORM SYNDROMENovember 2022January 2026Abandon3810NoNo
18056008PHENOTHIAZINE DERIVATIVES AND USES THEREOFNovember 2022July 2024Allow2010NoNo
18055579OLIGONUCLEOTIDE SYNTHESIZERNovember 2022January 2025Abandon2620NoNo
17982213ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITYNovember 2022August 2025Allow3330NoNo
17975790NATURAL AND SYNTHETIC COMPOUNDS FOR TREATING CANCER AND OTHER DISEASESOctober 2022December 2025Abandon3810NoNo
17970537GLYCAN COMPOSITIONS AND METHODS OF USEOctober 2022December 2025Abandon3810NoNo
18046261Far-Red Dye Probe FormulationsOctober 2022March 2026Allow4121NoNo
17960966COMPOSITIONS AND METHODS THAT ATTENUATE COGNITIVE AGING IN INDIVIDUALS WHO DO NOT HAVE DEMENTIAOctober 2022February 2025Abandon2820YesNo
179168625-POSITION MODIFIED PYRIMIDINESOctober 2022February 2026Abandon4010NoNo
17907714TREATMENT OF SEPSIS AND HYPERCYTOKINEMIASeptember 2022February 2026Allow4120NoNo
17914876ANTIVIRAL AGENTSeptember 2022January 2026Abandon3901NoNo
17947716TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOFSeptember 2022October 2024Allow2520YesNo
17906374ENASIDENIB GLYCOSIDES AND METHODS OF TREATING DISEASES ASSOCIATED WITH ISOCITRATE DEHYDROGENASE (IDH) DYSFUNCTIONSeptember 2022November 2025Abandon3801NoNo
17931491METHODS AND COMPOSITIONS TO PREVENT AND TREAT INFLAMMATION AND ALLERGIC REACTIONSSeptember 2022February 2025Abandon2921NoNo
17941835Nucleic Acid and Other Compositions and Methods for the Modulation of Cell MembranesSeptember 2022September 2024Allow2410NoNo
17939896MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOFSeptember 2022May 2025Allow3311NoNo
17802485Method And Apparatus for Enzymatic Synthesis of PolynucleotidesAugust 2022January 2026Allow4011NoNo
17852453COMPOSITION OF NOVEL CARBOHYDRATE DRUG FOR TREATMENT OF HUMAN DISEASESJune 2022August 2025Abandon3810NoNo
17850467PROTON ACTIVATED ATOMIC MEDICINEJune 2022February 2025Allow3221NoNo
17744255BIOLUMINESCENT DETECTION OF DNA SYNTHESISMay 2022December 2025Allow4320YesNo
17722513CD73 INHIBITORSApril 2022January 2025Abandon3320NoNo
17658547METHODS FOR TREATMENT AND PROPHYLAXIS OF HIV AND AIDSApril 2022August 2024Allow2820NoNo
17639918NOVEL BIS (HYDROXY BENZYLIDENE) CYCLIC KETONE BASED TETRA-AZA CORANDMarch 2022August 2025Allow4120NoNo
17639063COMPOUND AND DRUG CONJUGATE, AND PREPARATION METHOD AND USE THEREOFFebruary 2022September 2025Allow4210NoNo
17674032ANIMAL THERAPEUTIC AND FEED COMPOSITIONS AND METHODS OF USEFebruary 2022January 2025Abandon3520NoNo
17633941(2-ACETAMIDYL)THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVESFebruary 2022May 2025Allow3910NoNo
17633895(HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVESFebruary 2022April 2025Allow3910NoNo
17597343COMPOSITIONS AND METHODS USING TRIGONELLINE AND HIGH PROTEIN FOR PREVENTING OR TREATING CONDITIONS OR DISORDERS IN SKELETAL MUSCLEJanuary 2022October 2025Abandon4610NoNo
17596130REDUCED NICOTINAMIDERIBOSIDES FOR TREATING OR PREVENTING KIDNEY DISEASEDecember 2021September 2025Abandon4620YesNo
17615254SAPONIN PURIFICATIONNovember 2021August 2025Allow4520YesNo
17500099ANALOGUES OF OLEUROPEIN AND OLEACEIN AND USES THEREOFOctober 2021February 2024Abandon2811NoNo
17494320REGULATION OF DNA SYNTHESIS BY NUCLEOTIDES LINKED TO PROTECTING GROUPSOctober 2021May 2025Allow4310YesNo
17598040SEMI-SYNTHETIC BIOPOLYMERS FOR USE IN STIMULATING THE IMMUNE SYSTEMSeptember 2021March 2025Abandon4240NoNo
17458200DEVICES AND METHODS FOR SYNTHESISAugust 2021September 2025Allow4951YesNo
17397216COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERSAugust 2021October 2025Allow5060YesNo
17367115OLIGOSACCHARIDES COMPOSITION FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROMEJuly 2021October 2024Abandon4040NoNo
17351169Targeting LigandsJune 2021December 2024Abandon4220NoNo
17293577ANTI-CDH6 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATEMay 2021February 2026Abandon5711YesNo
17293370COMBINATION OF GOLD COMPLEXES WITH OLAPARIB OR OTHER PARP1/2 INHIBITORS FOR USE IN THE TREATMENT OF CANCER RESISTANT TO SAID PARP1/2 INHIBITORSMay 2021January 2025Abandon4510NoNo
17317614LOW-DOSE TRIPLE COMBINATION FORMULATIONMay 2021May 2025Abandon4840YesNo
17285233GALACTOSIDE INHIBITOR OF GALECTINSApril 2021August 2025Allow5250NoNo
17285253STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF YEAST-DERIVED POLYSACCHARIDE INDUCING TREG CELLApril 2021October 2024Allow4211YesNo
17215910INDUSTRIAL METHOD FOR SIMULTANEOUSLY PREPARING STEVIA REBAUDIANA CHLOROGENIC ACID AND STEVIOSIDEMarch 2021March 2026Allow5990NoNo
17278958DISULFIDE-LINKED REVERSIBLE TERMINATORSMarch 2021November 2024Allow4410NoNo
17277230Normalization of Nucleic Acid Samples and Compositions for Use in the SameMarch 2021September 2025Abandon5440YesNo
17269182METHODS AND COMPOSITIONS FOR NUCLEIC ACID ISOLATIONFebruary 2021November 2024Allow4520NoNo
17267666NOVEL GINSENOSIDE AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAMEFebruary 2021January 2024Allow3620NoNo
17265920OPTICALLY ACTIVE BRIDGED PIPERIDINE DERIVATIVEFebruary 2021March 2026Allow6060NoNo
17265794ANTIBIOTIC RESISTANCE-MODIFYING TRICYCLIC HETEROARYL COMPOUNDS AND USES THEREOFFebruary 2021May 2025Allow5240NoNo
16972456NOVEL HUMAN DIHYDROOROTATE DEHYDROGENASE (hDHODH) INHIBITORS AND THEIR USE IN TARGETING ONCOLOGICAL DISEASES SENSITIVE TO PYRIMIDINE STARVATIONDecember 2020July 2024Allow4420NoNo
17057164METHOD FOR SELECTING POLYNUCLEOTIDES BASED ON THE SIZE IN A GLOBULAR FORMNovember 2020September 2025Allow5840YesNo
17050424ABCB5 LIGANDS AND SUBSTRATESOctober 2020June 2025Allow5631NoNo
17049742NUCLEIC ACID ISOLATION AND INHIBITOR REMOVAL FROM COMPLEX SAMPLESOctober 2020May 2025Allow5430YesNo
170459864'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCEROctober 2020December 2025Abandon6040NoYes
17011880ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATESSeptember 2020December 2024Allow5231NoNo
16999483METHOD OF PRODUCTIONAugust 2020November 2024Abandon5130NoNo
16997255METHODS OF PROTECTING AN ORGAN USING TETRAHYDROCURCUMIN AND PHOSPHATIDYLCHOLINEAugust 2020February 2023Abandon3040NoYes
16913590TERNARY MIXTURES OF 6'-SL, LNnT and LST cJune 2020August 2025Abandon6030YesYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner OLSON, ANDREA STEFFEL.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
10
Examiner Affirmed
8
(80.0%)
Examiner Reversed
2
(20.0%)
Reversal Percentile
31.2%
Lower than average

What This Means

With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
50
Allowed After Appeal Filing
10
(20.0%)
Not Allowed After Appeal Filing
40
(80.0%)
Filing Benefit Percentile
24.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner OLSON, ANDREA STEFFEL - Prosecution Strategy Guide

Executive Summary

Examiner OLSON, ANDREA STEFFEL works in Art Unit 1693 and has examined 286 patent applications in our dataset. With an allowance rate of 92.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner OLSON, ANDREA STEFFEL's allowance rate of 92.0% places them in the 77% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by OLSON, ANDREA STEFFEL receive 2.70 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by OLSON, ANDREA STEFFEL is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a -2.8% benefit to allowance rate for applications examined by OLSON, ANDREA STEFFEL. This interview benefit is in the 8% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 26.0% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 51.2% of cases where such amendments are filed. This entry rate is in the 77% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 61.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 51% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 78.3% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 69.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 26.6% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.